Core Viewpoint - Zhen Dong Pharmaceutical (300158.SZ) announced that its associate company, Guangdong Longchuang Biopharmaceutical Co., Ltd., has achieved the primary research endpoint in the Phase III clinical trial of its project "Vaginal Lactobacillus Dual Live Bacteria Capsules" [1] Group 1: Product Development - The product is a compound preparation primarily composed of Lactobacillus gasseri and Lactobacillus rhamnosus, aimed at treating bacterial vaginosis caused by microbial imbalance [1] - Current conventional therapies for bacterial vaginosis (BV) mainly utilize antibiotics such as metronidazole, tinidazole, and clindamycin [1] Group 2: Clinical Research Findings - Long-term use of antibiotics can lead to drug resistance, making it ineffective in restoring vaginal microecology [1] - A Phase IIa clinical study indicated that the clinical cure rate of metronidazole is approximately 40% to 45% [1]
振东制药(300158.SZ):龙创基药业在研项目阴道用乳杆菌二联活菌胶囊达到主要研究终点